Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Short term Debt (2016 - 2017)

Lisata Therapeutics (LSTA) has disclosed Short term Debt for 8 consecutive years, with $3.2 million as the latest value for Q1 2017.

  • For the quarter ending Q1 2017, Short term Debt rose 175.58% year-over-year to $3.2 million, compared with a TTM value of $3.2 million through Mar 2017, up 175.58%, and an annual FY2016 reading of $3.1 million, down 25.05% over the prior year.
  • Short term Debt was $3.2 million for Q1 2017 at Lisata Therapeutics, up from $3.1 million in the prior quarter.
  • Across five years, Short term Debt topped out at $5.0 million in Q2 2016 and bottomed at $23175.0 in Q4 2013.
  • Average Short term Debt over 5 years is $2.3 million, with a median of $2.5 million recorded in 2015.
  • The sharpest move saw Short term Debt plummeted 99.32% in 2014, then soared 9578.41% in 2015.
  • Year by year, Short term Debt stood at $23175.0 in 2013, then soared by 4687.97% to $1.1 million in 2014, then skyrocketed by 275.94% to $4.2 million in 2015, then decreased by 25.05% to $3.1 million in 2016, then grew by 2.14% to $3.2 million in 2017.
  • Business Quant data shows Short term Debt for LSTA at $3.2 million in Q1 2017, $3.1 million in Q4 2016, and $2.3 million in Q3 2016.